April 8 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | -1.01% | -5.69% | -10.02% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,728 JPY | +0.85% | +2.71% | 9.15B | ||
169.4 USD | +0.01% | +5.57% | 299B | ||
26 USD | -1.01% | -5.69% | 1.44B | ||
0.25 USD | -16.67% | -28.57% | 373K | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.02% | 1.44B | |
+19.29% | 80.5B | |
+15.08% | 9.15B | |
-18.33% | 4.9B | |
+43.39% | 4.49B | |
+13.95% | 4.44B | |
+10.89% | 2.19B | |
-28.40% | 2.13B | |
+15.93% | 2.1B | |
-43.17% | 1.78B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease